Biscayne Pharmaceuticals
Is a clinical stage biotechnology company developing drugs
for difficult-to-treat conditions in two major disease areas

ABOUT

Biscayne Pharmaceuticals is a clinical stage biotechnology company developing drugs for difficult-to-treat conditions in two major disease areas: CNS disorders such as refractory epilepsy, and drug-resistant cancer. Both programs are based on novel approaches that have demonstrated potential for superior efficacy and safety, and both are based on innovative science that was discovered or championed by biomedical luminaries. Learn More

SCIENCE

Biscayne has two novel drug platforms that target hard-to-treat conditions with major unmet needs. Its CNS platform is based on a highly potent acetylcholinesterase inhibitor with demonstrated efficacy in highly predictive models of challenging epileptic conditions. Biscayne’s second program targets cancer using a novel molecular target– growth hormone-releasing hormone (GHRH) receptors. Learn More

News

Biscayne Pharmaceuticals Presents Data On Novel Antiepileptic Agent Bis-001 At Eilat Conference On New Antiepileptic Drugs

Biscayne Pharmaceuticals Presents Data At 2015 Aes Meeting Confirming Bis-001 Is A Novel Mechanism, Highly Potent And Well-Tolerated Anti-Epileptic Drug

New Study Published In Pnas Shows Biscayne’s Ghrh Agonists Could Increase The Feasiblity Of Beta Cell Transplants To Treat Type 1 Diabetes